About Us

Manufacturing, centered on quality.

Ramopharmin Pharmaceutical Company is a long-established Iranian manufacturer of finished-dosage medicines — tablets, capsules, syrups, and drops — produced under cGMP and internationally aligned quality systems. Building on decades of manufacturing heritage and a 2024 transition to private ownership, we combine disciplined quality with continuous research and reliable supply, at home and abroad.

1969
Established
100+
Products
4
Dosage forms
cGMP · WHO
Quality systems
Our Vision

A trusted name in quality — at home and on the global stage.

To stand among Iran's most trusted and forward-looking pharmaceutical manufacturers — a company whose name is synonymous with consistent quality, scientific rigor, and dependable supply. We are building beyond our domestic foundation toward regional and international markets, so that Iranian pharmaceutical manufacturing competes confidently — through modern technology, disciplined quality systems, and an unwavering focus on public health.

Our Mission

To produce and supply safe, effective, high-quality medicines — made to recognized standards and kept within reach of the patients who need them. We regard the quality of our medicines, above all, as a responsibility to public health, and through up-to-date science, disciplined processes, and close cooperation with physicians, pharmacists, and distributors, we work to earn and keep the trust of the people and communities we serve.

Quality & Compliance

cGMP and WHO-aligned quality systems, rigorous quality assurance and control, and active pharmacovigilance.

Research & Development

Continuous formulation development, technology transfer, and the modernization of our processes and facilities.

Responsibility to Public Health

Reliable supply of essential medicines and an ethical commitment to the patients and communities we serve.

Our History

From heritage to a modern future.

1969
Founded in Tehran

Registered in Tehran (No. 13150) as a limited-liability pharmaceutical company.

1980
Private joint-stock company

Converted to a private joint-stock company as operations and product range grew.

2024
New private ownership

Ownership transferred to the Khesht Investment Group, opening a new chapter of investment and modernization.

Today
Modernization & export readiness

Structural, quality, and digital transformation toward consistent commercial supply and international markets.

At a Glance

Company profile.

Company type
Private joint-stock
Ownership
Khesht Investment Group
Headquarters
Tehran, Iran
Quality systems
cGMP · WHO-aligned · ISO 9001
Dosage forms
Tablets · Capsules · Syrups · Drops
Therapeutic groups
8 groups · 100+ products
Flagship product
Azaram® (azathioprine)
Market focus
Domestic supply + export
Get in touch

Learn more about Ramopharmin.

Explore our product range, or reach out about distribution, export, and partnership opportunities.